BioSpace News Archive

The Medical Device Innovation Consortium (MDIC) has announced the release of its Leadership Engagement Playbook of best practices and tools to help leaders move their companies from a culture of compliance to a culture of quality.

Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.

Waters Corporation Presentation at the 41 st Annual Cowen Healthcare Conference to Be Audio Webcast Live

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Identification Panels.

- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.

- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 1, 2021.

Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the fourth quarter and full year 2020 before the U.S. market opens on Tuesday, March 2, 2021.

NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 Positive Phase 3 data on topical roflumilast cream in plaque psoriasis reported in February Advancing topical roflumilast into Phase 3 programs for atopic dermatitis, seborrheic dermatitis, and scalp psoriasis during 2021 Robust pipeline addressing unmet medical needs of over 20 million patients

iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18 th at 4:30pm ET

Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders